+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety, tolerability, immune response, and pharmacokinetics of UGN-501, a chimeric oncolytic adenovirus, given directly into the bladder for adults with recurrent non-muscle invasive bladder cancer NMIBC. This Phase 1, open-label, dose-escalation study focuses on participants with high-grade and low-grade Ta andor T1 disease or carcinoma in situ CIS, aiming to find the recommended dose for further study. Participants will undergo a 12-week Induction Period with six weekly intravesical instillations of UGN-501. Those with certain disease types who respond or do not have recurrence will continue into a Maintenance Period, receiving three weekly instillations every three months from Month 3 to Month 12. Disease assessments occur every three months up to 15 months or until recurrence, progression, or death. The study may add other intervention arms or dose expansions in future amendments. During the study, participants will have regular evaluations including monitoring for dose-limiting toxicities, adverse events, drug levels in blood and urine, and immune response. Disease status will be assessed at specified intervals, with follow-up lasting up to 15 months. The main outcomes measured include safety, complete response rate at 3 months, and recurrence-free survival at 6 months, along with detailed pharmacokinetic and viral shedding analyses.

Age: 18Years +All GendersPhase 1
15 locations
P

Actively Recruiting

Researchers are studying UGN-104, a new form of UGN-101 also known as JELMYTO, to evaluate its safety and effectiveness for treating low-grade upper tract urothelial cancer LG-UTUC. This phase 3 study focuses on patients with this type of cancer located in the upper urinary tract. The research aims to understand how well UGN-104 works when placed directly into the affected area and to monitor its safety during treatment. Participants will receive UGN-104 once a week for six weeks, totaling six doses. This medication combines mitomycin with a special gel that becomes semi-solid at body temperature, allowing it to stay in the urinary tract longer. After about three months from the first dose, patients undergo evaluation to check for complete response, which includes urine tests and visual exams of the urinary tract. Those who respond completely may receive monthly maintenance doses of UGN-104 for up to 11 months. Patients who do not respond fully complete the study at this point. Throughout the study, participants will have regular clinic visits every three months for up to a year after their initial evaluation or until the cancer returns, worsens, or the patient passes away. Assessments include urine cytology, ureteroscopy, biopsies if needed, and laboratory tests to monitor mitomycin levels and side effects. Researchers will track treatment response duration, safety events, and drug concentrations to better understand the therapy and its effects over time.

Age: 18Years +All GendersPhase 3
79 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of an investigational treatment called T3011 in people with non-muscle invasive bladder cancer NMIBC that has not responded to standard therapies like BCG or chemotherapy. This Phase II study focuses on patients with high-risk or intermediatehigh-risk NMIBC who have limited treatment options after previous therapies have failed. Participants receive T3011 as an injection into the bladder once a week for six weeks during an induction phase. After a rest period, a 3-month evaluation determines if further treatment is needed. Those with no recurrence or complete response enter a maintenance phase where T3011 is given every three weeks for up to about 24 months. The study includes different cohorts based on cancer characteristics and prior treatments. Throughout the study, participants undergo regular cystoscopy, urine cytology, and imaging as needed every three months to monitor disease status. Researchers will track response rates, recurrence-free survival, and any treatment-related adverse events for up to 24 months. Participants are expected to comply with study procedures and follow-up assessments during this time.

Age: 18Years +All GendersPhase 2
9 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness of an AI-based treatment strategy using a Chatbot, Copilot, large language models, and vital sign monitoring devices to reduce the burden of Cardio Kidney Metabolic CKM diseases. This study focuses on patients with interconnected conditions including diabetes, heart disease, and kidney disease, which have significant health and economic impacts. The trial aims to use an algorithm derived from biomarkers and diagnostics combined with remote sensor technology and patient empowerment to improve health outcomes in this population. Participants will be assigned randomly to either an intervention group receiving the CHAPERONE AI treatment or a control group. The intervention uses machine learning-based Chatbot and Copilot tools along with algorithms informed by biomarkers and diagnostics to manage CKM diseases. The study will assess outcomes at 30, 90, and 180 days, including reduction in kidney failure progression, heart failure events, acute myocardial infarction, diabetes complications, hospitalizations, and mortality. Additional tools such as the CKMiq AI device will be used to monitor cardiovascular readmissions and patient well-being through established scoring systems. During the trial, participants will undergo assessments of their health status, including biomarker analysis, diagnostic tests, and quality of life surveys like the SF-12. Researchers will monitor composite outcomes related to kidney and heart disease progression and hospital readmissions. Data will be collected at multiple time points to evaluate the impact of the AI-driven intervention on disease management and patient empowerment over six months. Safety and health status will be followed up for the duration of participation, which begins at enrollment and continues through 180 days.

Age: 18Years +All GendersPhase Not Applicable
5 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TARA-002 for treating high-grade non-muscle invasive bladder cancer NMIBC in adults 18 years and older who have not previously received BCG treatment. This Phase 3 randomized study aims to compare TARA-002 with chemotherapy chosen by investigators to see if TARA-002 can help participants with this type of bladder cancer and to understand its side effects. Participants will receive either six weekly doses of TARA-002 or six weekly doses of intravesical chemotherapy. Those who achieve a complete response at Week 12 will enter a maintenance phase. For TARA-002, maintenance involves three weekly doses every three months up to Month 19, then three weekly doses at Month 25. Participants eligible for reinduction at Week 12 may receive six additional weekly doses, followed by the same maintenance schedule if they respond at Week 24. For chemotherapy, maintenance involves one dose every month up to Month 25. During the study, participants will undergo assessments to measure the incidence of complete response at six months and other outcomes up to five years, including duration of response, recurrence, progression, survival, and safety events. Regular monitoring will include evaluating side effects and long-term outcomes such as time to surgery and disease worsening. The total participation may last up to 60 months to fully assess these outcomes.

Age: 18Years +All GendersPhase 3
11 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.

Age: 18Years +All GendersPhase 2
78 locations